ROSEN, MASTER DRIVER ADVISOR, Encourages Humacyte, Inc. Investors. Defending Counsel Before the Important January 17 Securities Class Action Deadline
New York, New York–(Newsfile Corp. – January 4, 2025) – WHY: The Rosen Law Firm, a global investor rights law firm, reminds consumers of the securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”), of material importance. January 17, 2025 is the deadline for the plaintiff.
NOW: If you purchased Humacyte securities during the Class Period you may be entitled to compensation without payment of any out-of-pocket costs or expenses through a contingency fund plan.
WHAT YOU NEED TO DO: To join the Humacyte class action, visit or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you wish to act as the lead plaintiff, you must remove the Court no later than January 17, 2025. The lead plaintiff is the organization representing the other members of the class directing the lawsuit.
WHY DID THE LAW COME OUT: We encourage investors to choose qualified advisors with a track record of success in leadership roles. Generally, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these companies are not responsible for the actions of the security department, but they are partners who send customers or partners with law firms who prosecute cases. Be wise in choosing advice. The Rosen Law Firm represents investors worldwide, focusing its practice on securities class actions and shareholder exit litigation. The Rosen Law Firm won the largest securities class action settlement ever against a Chinese Company at the time. The Rosen Law Firm is ranked #1 by ISS Securities Class Action (WA:) Value services for securities class agreements in 2017. The company has been listed in the top 4 every year since 2013 and has returned hundreds of millions of dollars to investors. In 2019 alone the company secured more than 438 million from investors. In 2020, founding partner Laurence Rosen was named by Law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s lawyers are recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, during the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) Humacyte’s Durham, North Carolina facility failed to comply with good manufacturing practices, including quality assurance and microbial testing. ; (2) Food and Drug Administration (“FDA”) review of Biologics’ license application (“BLA”) will be delayed while Humacyte corrects these deficiencies; and (3) as a result, there was a significant risk to the FDA’s approval of the Acellular Tissue Engineered Vessel (“ATEV”) for vascular trauma; and (4) as a result of the foregoing, the defendants’ positive statements about Humacyte’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When true information enters the market, the lawsuit claims that investors suffered damages.
To join a Humacyte class action, visit or call Phillip Kim, Esq. toll free at 866-767-3653 or email case@rosenlegal.com for information about the class action.
No Class Guaranteed. Until the class is certified, you are not represented by an attorney unless you retain it. You can choose the advice of your choice. You can also remain a member of the absent class and do nothing for now. The investor’s ability to participate in any potential future returns is not dependent on performance as the lead claimant.
Follow us for updates on LinkedIn: on Twitter: or on Facebook (NASDAQ:):
Advocate advertising. Previous results do not guarantee the same result.
——————————
Contact information:
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236071
